Embattled Salix hires bankers to weigh a potential sale

Salix Pharmaceuticals ($SLXP) has taken a step toward a potential sale. Haunted by an inventory snafu and a C-suite shakeup, the company was already facing investor pressure to look for bidders once its supply issues were resolved. Now, Salix has tapped Crestview Partners to "explore options" as it hunts for a new CEO. No decision is expected until after that person comes on board, however. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

Roche Canada's new innovation challenge to fight COVID-19 has an April 10 deadline and promises up to $100,000 to fund development.

Merck, Eli Lilly and Pfizer have launched or expanded volunteer programs to dedicate medical workers to the COVID-19 effort.